Roy M Fleischmann

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. ncbi request reprint Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept
    Roy Fleischmann
    Radiant Research Dallas, Dallas, Texas 75235, USA
    Drug Saf 25:173-97. 2002
  2. ncbi request reprint Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
    Roy Fleischmann
    Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235 5360, USA
    Expert Opin Biol Ther 4:1333-44. 2004
  3. ncbi request reprint Is there a need for new therapies for rheumatoid arthritis?
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas, USA
    J Rheumatol Suppl 73:3-7; discussion 29-30. 2005
  4. ncbi request reprint Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    R M Fleischmann
    Radiant Research Dallas, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75235, USA
    Curr Med Res Opin 21:1181-90. 2005
  5. ncbi request reprint Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Radiant Research Dallas, 5939 Harry Hines Boulevard, Dallas, 75235, USA
    Clin Rheumatol 25:42-53. 2006
  6. pmc Long term safety of etanercept in elderly subjects with rheumatic diseases
    R Fleischmann
    University of Texas Southwestern Medical Center at Dallas, 5939 Harry Hines Boulevard, Dallas, Texas 75235, USA
    Ann Rheum Dis 65:379-84. 2006
  7. ncbi request reprint Tacrolimus in rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Centre at Dallas, USA
    Expert Opin Pharmacother 7:91-8. 2006
  8. pmc Safety of extended treatment with anakinra in patients with rheumatoid arthritis
    R M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, 5939 Harry Hines Boulevard, Dallas, TX 75235, USA
    Ann Rheum Dis 65:1006-12. 2006
  9. ncbi request reprint Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Rheum Dis Clin North Am 32:21-8. 2006
  10. ncbi request reprint Anakinra in the treatment of rheumatic disease
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400 Dallas, TX 75235, USA
    Expert Rev Clin Immunol 2:331-40. 2006

Detail Information

Publications39

  1. ncbi request reprint Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept
    Roy Fleischmann
    Radiant Research Dallas, Dallas, Texas 75235, USA
    Drug Saf 25:173-97. 2002
    ..Preliminary data show that it may be well tolerated and effective in other rheumatic diseases in which there is over production of TNFalpha...
  2. ncbi request reprint Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
    Roy Fleischmann
    Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235 5360, USA
    Expert Opin Biol Ther 4:1333-44. 2004
    ..Anakinra should not be given in combination with anti-TNF agents...
  3. ncbi request reprint Is there a need for new therapies for rheumatoid arthritis?
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas, USA
    J Rheumatol Suppl 73:3-7; discussion 29-30. 2005
    ..This approach will be examined in this and the following articles...
  4. ncbi request reprint Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial
    R M Fleischmann
    Radiant Research Dallas, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75235, USA
    Curr Med Res Opin 21:1181-90. 2005
    ..We evaluated the ability of patients receiving infliximab plus MTX to achieve and maintain a clinical response while the dose of MTX was tapered...
  5. ncbi request reprint Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Radiant Research Dallas, 5939 Harry Hines Boulevard, Dallas, 75235, USA
    Clin Rheumatol 25:42-53. 2006
    ..Lumiracoxib demonstrated a tolerability profile similar to placebo and celecoxib...
  6. pmc Long term safety of etanercept in elderly subjects with rheumatic diseases
    R Fleischmann
    University of Texas Southwestern Medical Center at Dallas, 5939 Harry Hines Boulevard, Dallas, Texas 75235, USA
    Ann Rheum Dis 65:379-84. 2006
    ....
  7. ncbi request reprint Tacrolimus in rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Centre at Dallas, USA
    Expert Opin Pharmacother 7:91-8. 2006
    ..This article reviews the pharmacodynamics, pharmacokinetics, clinical efficacy, safety and role of tacrolimus in the treatment of rheumatoid arthritis...
  8. pmc Safety of extended treatment with anakinra in patients with rheumatoid arthritis
    R M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, 5939 Harry Hines Boulevard, Dallas, TX 75235, USA
    Ann Rheum Dis 65:1006-12. 2006
    ..To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis...
  9. ncbi request reprint Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Rheum Dis Clin North Am 32:21-8. 2006
  10. ncbi request reprint Anakinra in the treatment of rheumatic disease
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400 Dallas, TX 75235, USA
    Expert Rev Clin Immunol 2:331-40. 2006
    ....
  11. pmc Does safety make a difference in selecting the right TNF antagonist?
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Arthritis Res Ther 6:S12-8. 2004
    ..Overall, the anti-TNF agents are well tolerated and have demonstrated a favorable benefit-to-risk profile in patients with RA...
  12. ncbi request reprint Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Mol Interv 3:310-8. 2003
  13. ncbi request reprint Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial
    Roy M Fleischmann
    St Paul University Hospital, Dallas, Texas 75235, USA
    Arthritis Rheum 48:927-34. 2003
    ..To evaluate the safety of anakinra (a recombinant human interleukin-1 receptor antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those seen in clinical practice...
  14. ncbi request reprint Addressing the safety of anakinra in patients with rheumatoid arthritis
    R M Fleischmann
    St Paul University Hospital, Department of Rheumatology, Dallas, TX 75235, USA
    Rheumatology (Oxford) 42:ii29-35. 2003
    ..This confirmed that anakinra is a well-tolerated treatment in an RA population representative of that seen by the practising rheumatologist...
  15. ncbi request reprint Meloxicam
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA
    Expert Opin Pharmacother 3:1501-12. 2002
    ..Adverse events, including peripheral oedema and hypertension, occurred at a similar rate as with traditional NSAIDs...
  16. ncbi request reprint Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, St Paul University Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235, USA
    Expert Opin Drug Saf 2:347-65. 2003
    ....
  17. ncbi request reprint Examining the efficacy of biologic therapy: are there real differences?
    Roy M Fleischmann
    Department of Medicine, St Paul University Hospital, University of Texas Southwestern Medical Center, Dallas 75235, USA
    J Rheumatol Suppl 65:27-32. 2002
    ..All 3 biologics - anakinra, etanercept, and inflixmab - are effective...
  18. ncbi request reprint Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents
    R M Fleishmann
    University of Texas, Southwestern Medical Center at Dallas Dallas, Texas, USA
    Clin Exp Rheumatol 20:S35-41. 2002
    ..Post approval, several safety concerns, including patients at risk for serious infection and the emergence of latent tuberculosis and other opportunistic infections have emerged with the use of anti TNF therapy...
  19. ncbi request reprint Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
    Roy M Fleischmann
    University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235 5360, USA
    Expert Opin Drug Saf 3:391-403. 2004
    ..It is important to be fully aware of the safety profile and differences between BRMs in order to use them appropriately...
  20. ncbi request reprint Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results
    Roy M Fleischmann
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Rheumatol 30:691-6. 2003
    ..We compared the safety and efficacy of etanercept (Enbrel) in patients with RA who were > or = 65 years to those < 65 years in open-label and double-blind, randomized clinical trials...
  21. ncbi request reprint Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
    Daniel E Furst
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, 32 59 Rehabilitation Center, 1000 Veteran Avenue, Box 951670, Los Angeles, CA 90095 1670, USA
    J Rheumatol 30:2563-71. 2003
    ..Standard antirheumatic therapy included traditional disease modifying antirheumatic drugs (DMARD), low dose corticosteroids, nonsteroidal antiinflammatory drugs (NSAID), and/or analgesics...
  22. ncbi request reprint Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
    ..In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA...
  23. doi request reprint Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results
    Roy M Fleischmann
    Metroplex Clinic Research Center, Dallas, Texas, USA Panorama Medical Center, Cape Town, South Africa
    J Rheumatol 40:113-26. 2013
    ....
  24. ncbi request reprint Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 46:1443-50. 2002
    ..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy...
  25. pmc Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
    BMC Musculoskelet Disord 9:32. 2008
    ..d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year...
  26. ncbi request reprint The efficacy and safety of golimumab in the treatment of arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical School, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, Texas 75231, USA
    Expert Opin Biol Ther 10:1131-43. 2010
    ..Biologic therapies have dramatically changed the long-term prognosis of patients with rheumatoid and psoriatic arthritis and ankylosing spondylitis...
  27. doi request reprint Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab
    Roy M Fleischmann
    University of Texas Southwestern Medical Center, and Metroplex Clinical Research Center, Dallas, TX 75235 5360, USA
    Semin Arthritis Rheum 38:265-80. 2009
    ..To review the safety of biologic agents used to treat rheumatoid arthritis (RA) and other autoimmune diseases, with a focus on rituximab...
  28. ncbi request reprint Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Drugs Aging 24:239-54. 2007
    ..Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNFalpha therapies, be determined by the practising physician and the patient...
  29. ncbi request reprint Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis
    John Tesser
    University of Arizona Health Sciences Center, Arizona Rheumatology Center, Phoenix, Arizona 85015 2160, USA
    J Rheumatol 31:649-54. 2004
    ..To examine the safety of anakinra when added to a background of standard rheumatoid arthritis (RA) medications in patients with RA with active disease...
  30. ncbi request reprint A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis
    Daniel E Furst
    Department of Rheumatology, University of California at Los Angeles, California 90095, USA
    J Rheumatol 32:2303-10. 2005
    ..In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA)...
  31. doi request reprint The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, Texas 75231, USA
    Expert Opin Biol Ther 10:773-86. 2010
    ..Another medication, such as certolizumab pegol, is a welcome addition to our treatment armamentarium of rheumatoid arthritis...
  32. ncbi request reprint Primer: establishing a clinical trial unit - regulations and infrastructure
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, and Metroplex Clinical Research Center, Dallas, TX 75235, USA
    Nat Clin Pract Rheumatol 3:234-9. 2007
    ..The purpose of this article is to review these requirements in depth, as well as to discuss the infrastructure required to establish a successful clinical trial unit...
  33. ncbi request reprint Primer: establishing a clinical trial unit--obtaining studies and patients
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Nat Clin Pract Rheumatol 3:459-63. 2007
    ..If done properly, however, clinical investigation can be rewarding--both intellectually and financially...
  34. doi request reprint Kinase inhibitors: a new approach to rheumatoid arthritis treatment
    Stanley Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Curr Opin Rheumatol 22:330-5. 2010
    ..This article will review the recent publications on these efforts...
  35. ncbi request reprint Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability
    Scott W Baumgartner
    Physician s Clinic of Spokane, Spokane, Washington 99204, USA
    J Rheumatol 31:1532-7. 2004
    ..To compare etanercept-induced improvement in disability of patients with recent onset of rheumatoid arthritis (RA) to that of patients with established RA...
  36. ncbi request reprint Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Rheumatol 32:1232-42. 2005
    ..To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept...
  37. ncbi request reprint Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations
    Joel M Kremer
    The Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 48:1493-9. 2003
    ....
  38. ncbi request reprint Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis
    Honghui Zhou
    Clinical Pharmacology and Experimental Medicine, Centocor Research and Development, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Clin Pharmacol 47:383-96. 2007
    ..0%. Body weight was found to be an important covariate on V(c). Golimumab was generally well tolerated. The pharmacokinetics of golimumab appeared to be linear over the dose range evaluated in this study...
  39. ncbi request reprint Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis
    Joan M Bathon
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA
    J Rheumatol 33:234-43. 2006
    ..To evaluate safety and efficacy of etanercept treatment in elderly (age > or = 65 yrs) and younger adult subjects (age < 65 yrs) with rheumatoid arthritis (RA)...